Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium.

Pattee GL, Plowman EK, Brooks BR, Berry JD, Atassi N, Chapin JL, Garand K, Yunusova Y, Mcilduff CE, Young E, Costello JM, Macklin EA, Locatelli ER, Silani V, Heitzman D, Wymer J, Goutman SA, Gelinas DF, Smith R, Perry B, Nalipinski P, Stipancic K, O'Brien M, Sullivan SL, Green J; CONTRIBUTING MEMBERS OF THE NEALS BULBAR SUBCOMMITTEE.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):311-312. doi: 10.1080/21678421.2017.1404109. Epub 2017 Dec 5.

PMID:
29205054
2.

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinas DF, Lou JS.

Amyotroph Lateral Scler. 2008 Oct;9(5):266-72. doi: 10.1080/17482960802028890.

3.

Hope in palliative care: from narcissism to self-transcendence in amyotrophic lateral sclerosis.

Fanos JH, Gelinas DF, Foster RS, Postone N, Miller RG.

J Palliat Med. 2008 Apr;11(3):470-5. doi: 10.1089/jpm.2007.0098.

PMID:
18363490
4.
5.

MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS).

Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Lancero M, Narvaez A, McGrath MS.

J Neuroimmunol. 2006 Oct;179(1-2):87-93. Epub 2006 Jul 20.

PMID:
16857270
6.

Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS).

Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, Jin X, Reis J, Narvaez A, McGrath MS.

J Neuroimmunol. 2005 Feb;159(1-2):215-24. Epub 2004 Nov 26.

PMID:
15652422
7.

Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study.

Rule RR, Suhy J, Schuff N, Gelinas DF, Miller RG, Weiner MW.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5(3):141-9.

8.

"You have shown me my end": attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis.

Fanos JH, Gelinas DF, Miller RG.

Am J Med Genet A. 2004 Sep 1;129A(3):248-53.

PMID:
15326623
9.

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis.

Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, Mendoza M, Mass J, Kushner G, Miller RG.

Neurology. 2004 May 25;62(10):1845-7.

PMID:
15159491
10.

Pulmonary function screening.

Gelinas DF.

Semin Neurol. 2003 Mar;23(1):89-96. Review.

PMID:
12870110
11.

Vital capacity as an efficacy measure: Summary.

Gelinas DF.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3 Suppl 1:S61-2. No abstract available.

PMID:
12396810
12.

A placebo-controlled trial of gabapentin in spinal muscular atrophy.

Miller RG, Moore DH, Dronsky V, Bradley W, Barohn R, Bryan W, Prior TW, Gelinas DF, Iannaccone S, Kissel J, Leshner R, Mendell J, Mendoza M, Russman B, Samaha F, Smith S; SMA Study Group.

J Neurol Sci. 2001 Oct 15;191(1-2):127-31.

PMID:
11677003
13.

Riluzole.

Gelinas DF.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1 Suppl 4:3-4. Review. No abstract available.

PMID:
11466957
14.

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.

Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R; Western ALS Study Group.

Neurology. 2001 Apr 10;56(7):843-8.

PMID:
11294919
15.

Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis.

Schuff N, Rooney WD, Miller R, Gelinas DF, Amend DL, Maudsley AA, Weiner MW.

Magn Reson Med. 2001 Mar;45(3):513-6.

16.

Blunted pressor and intramuscular metabolic responses to voluntary isometric exercise in multiple sclerosis.

Ng AV, Dao HT, Miller RG, Gelinas DF, Kent-Braun JA.

J Appl Physiol (1985). 2000 Mar;88(3):871-80.

17.

Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review).

Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA.

Muscle Nerve. 1999 Aug;22(8):1104-18. No abstract available.

PMID:
10417794
18.

Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies.

Damiano AM, Patrick DL, Guzman GI, Gawel MJ, Gelinas DF, Natter HM, Ingalls KK.

Med Care. 1999 Jan;37(1):15-26.

PMID:
10413388
19.

Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

Ackerman SJ, Sullivan EM, Beusterien KM, Natter HM, Gelinas DF, Patrick DL.

Pharmacoeconomics. 1999 Feb;15(2):179-95.

PMID:
10351191
20.

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.

Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA.

Neurology. 1999 Apr 22;52(7):1311-23. No abstract available.

PMID:
10227612

Supplemental Content

Loading ...
Support Center